SRZN
SRZN
NASDAQ · Biotechnology

Surrozen Inc

$28.90
+0.90 (+3.21%)
As of Mar 29, 10:35 PM ET ·
Financial Highlights (FY 2026)
Revenue
41.73M
Net Income
-248,939,901
Gross Margin
Profit Margin
-596.6%
Rev Growth
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 61.1% 61.1% 61.1%
Operating Margin -239.7% -7.1% -7.9% -7.5%
Profit Margin -596.6% -6.3% -5.7% -7.5%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 41.73M 55.50M 49.01M 58.73M
Gross Profit 33.90M 29.94M 35.88M
Operating Income -100,020,017 -3,914,644 -3,884,365 -4,377,578
Net Income -248,939,901 -3,521,463 -2,802,997 -4,374,334
Gross Margin 61.1% 61.1% 61.1%
Operating Margin -239.7% -7.1% -7.9% -7.5%
Profit Margin -596.6% -6.3% -5.7% -7.5%
Rev Growth +7.8% +7.4% -1.1%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 86.95M 78.39M 78.23M
Total Equity 98.70M 95.79M 82.86M
D/E Ratio 0.88 0.82 0.94
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -170,041,161 -5,026,082 -4,562,575 -6,395,991
Free Cash Flow -3,518,270 -4,055,082 -5,438,545